Skip to content

Omics-based Precision Medicine of Epilepsy

Omics-based Precision Medicine of Epilepsy Being Entrusted by Key Research Project of the Ministry of Science and Technology of China

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03358459
Enrollment
10000
Registered
2017-11-30
Start date
2017-11-25
Completion date
2018-07-01
Last updated
2017-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clinical Disease and/or Syndrome, Epilepsy Idiopathic, Gene Mutation

Keywords

phenotype; genotype

Brief summary

Epilepsy is a major disease of the nervous system (WHO, 2015), as well as the second most common neural disease. It has been recorded that there have been 65 million epilepsy patients all over the world, more than 10 million in China, resulted in high morbidity, high mortality, heavy social and social psychological burden. Due to complex etiology, which genetic playing a large part for 70%-80%, easy to recurrent, as well as various seizure types, a great heterogeneity in clinical manifestation, epilepsy is difficult to treat in general, at least 33% patients. At present, It's still a big challenge in early warning, choice of treatment, efficacy and severe adverse reaction rate, prognosis assessment. Lack of precise diagnosis based genetic and molecular bio-markers for treatment are the main key points. Recently, clinical phenotype classifications of epilepsy have been refined, the exist researches had made a progress in gene mutation mechanism and targeted therapy, which pushed epilepsy being another disease could be precise treated after tumor. It's sure to provide a breakthrough for another neural diseases if epilepsy precise treatment project are successful.

Detailed description

Research projects: Part 1: Based on already existed large samples of epilepsy clinical cases, choose 2,0000 non-acquired epilepsy patients for clinical general phenotype and middle phenotype(EEG and MRI) data collection to further multi-dimensional standardization measure and evaluate. Through metabolic detection to define micro-phenotype. Establish a standardized clinical and biological samples database. Part 2: By NGS technology to sequence for all cases, including family members, then require genotype. To test brain tissue DNA somatic mutation, which MRI negative and had an operation. To verify the newly discovered pathogenic candidate genes and carry on functional studies. Finally, to draw epileptic genetic mutations mapping in Chinese people. Part 3: Integrated clinical and genetic epilepsy phenotypic data, combined with neural EEG and image bitmap data points for bio-markers analysis, included early warning, classification of diagnosis, curative effect prediction and epilepsy con-morbidity disease.

Interventions

OTHERnon

non

Sponsors

Huashan Hospital
CollaboratorOTHER
Peking University First Hospital
CollaboratorOTHER
Peking University People's Hospital
CollaboratorOTHER
Xiangya Hospital of Central South University
CollaboratorOTHER
First Affiliated Hospital of Chongqing Medical University
CollaboratorOTHER
Children's Hospital of Chongqing Medical University
CollaboratorOTHER
Xuanwu Hospital, Beijing
CollaboratorOTHER
Capital Medical University
CollaboratorOTHER
Second Affiliated Hospital of Guangzhou Medical University
CollaboratorOTHER
Fudan University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
No minimum to 65 Years
Healthy volunteers
No

Inclusion criteria

* non-acquired epilepsy; family involved(children, father and mother); Han nationality; Consent and will to follow up

Exclusion criteria

* Acquired epilepsy; Very low birth weight infant

Design outcomes

Primary

MeasureTime frameDescription
The important bio-markers for the efficient therapy and prognosis2017.02-2018.07the gene mutation or chromosome missing or duplication

Countries

China

Contacts

Primary ContactWang yi, Dr
yiwang@shmu.edu.cn+8613564766228
Backup ContactLong Shasha, Dr
longshasha9985@sina.com+8615721029985

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026